0001399529-21-000104.txt : 20210607 0001399529-21-000104.hdr.sgml : 20210607 20210607213258 ACCESSION NUMBER: 0001399529-21-000104 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210603 FILED AS OF DATE: 20210607 DATE AS OF CHANGE: 20210607 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Doberstein Stephen K CENTRAL INDEX KEY: 0001480111 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36281 FILM NUMBER: 211001086 MAIL ADDRESS: STREET 1: 129 ELSIE STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dicerna Pharmaceuticals Inc CENTRAL INDEX KEY: 0001399529 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205993609 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 75 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617 621 8097 MAIL ADDRESS: STREET 1: 75 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 wf-form4_162311596214632.xml FORM 4 X0306 4 2021-06-03 0 0001399529 Dicerna Pharmaceuticals Inc DRNA 0001480111 Doberstein Stephen K C/O DICERNA PHARMACEUTICALS, INC. 75 HAYDEN AVENUE LEXINGTON MA 02421 1 0 0 0 Common Stock 2021-06-03 4 M 0 3333 A 3333 D Restricted Stock Units 2021-06-03 4 M 0 3333 0 D Common Stock 3333.0 0 D Restricted Stock Units 2021-06-03 4 A 0 3333 0 A Common Stock 3333.0 3333 D Director Stock Option (Right to Buy) 30.47 2021-06-03 4 A 0 15000 0 A 2031-06-02 Common Stock 15000.0 15000 D Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock. Represents RSUs that vested and became nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on June 3, 2021. Represents RSUs that shall vest and become nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on the earlier of (i) 12 months from June 3, 2021 ("Grant Date") and (ii) the next regularly scheduled annual meeting of stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through such date or, if earlier, such annual meeting. This option vests monthly over 12 months from the Grant Date in substantially equal monthly installments, provided that the option will vest in full on the next regularly scheduled annual meeting of the stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting. /s/ Douglas W. Pagan, attorney-in-fact 2021-06-07